Literature DB >> 8862564

Use of multiple PCR primer sets for optimal detection of human papillomavirus.

F Karlsen1, M Kalantari, A Jenkins, E Pettersen, G Kristensen, R Holm, B Johansson, B Hagmar.   

Abstract

Using multiple PCR primer sets, we tried to optimize the detection of human papillomavirus (HPV) in DNA samples isolated from 361 frozen biopsy specimens from patients with invasive cervical carcinomas. The HPVs detected were placed into three distinct groups, including group I/Inex at Telelab (Skien, Norway) and group Ineg and group II at the Norwegian Radium Hospital (Oslo, Norway). The consensus primer sets were Oli-1b-oli-2i, My09-My11, Gp5-Gp6, and Gp(5+)-Gp6+ from the HPV L1 gene and CpI-CpIIG from the E1 gene. Using these consensus primers together with the type-specific primers from E6-E7, we found that 355 patients (98%) were HPV positive. Type-specific primers for HPV types 11, 16, 18, 31, 33, and 35 detected more HPV-infected patients than the most sensitive consensus primer set, while the three consensus primer sets My, Gp/Gp+, and Cp together detected more HPV-positive patients than the type-specific primers. Testing of sensitivity of the PCR with SiHa cells serially diluted in lymphocytes (HPV-negative cells) indicated a detection limit of 6,300 HPV type 16 DNA copies with consensus primers (My, Gp+, and Cp) and 126 original HPV type 16 DNA copies with type-specific primers. Comparison of the amplification results for consensus L1 primers and type-specific E6-E7 primers indicated the presence of L1 deletions in 23 of 56 samples. The conclusion is that in PCR detection systems, multiple consensus primers and type-specific primers should be used in order to detect all patients harboring HPV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862564      PMCID: PMC229196          DOI: 10.1128/jcm.34.9.2095-2100.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  Comparison of ViraPap, Southern hybridization, and polymerase chain reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer.

Authors:  E Guerrero; R W Daniel; F X Bosch; X Castellsagué; N Muñoz; M Gili; P Viladiu; C Navarro; M L Zubiri; N Ascunce
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

2.  The incidence of HPV in a Swedish series of invasive cervical carcinoma.

Authors:  B Hagmar; B Johansson; M Kalantari; Z Petersson; B Skyldberg; L Walaas
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

3.  The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain.

Authors:  N Muñoz; F X Bosch; S de Sanjosé; L Tafur; I Izarzugaza; M Gili; P Viladiu; C Navarro; C Martos; N Ascunce
Journal:  Int J Cancer       Date:  1992-11-11       Impact factor: 7.396

4.  Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers.

Authors:  L M Tieben; J ter Schegget; R P Minnaar; J N Bouwes Bavinck; R J Berkhout; B J Vermeer; M F Jebbink; H L Smits
Journal:  J Virol Methods       Date:  1993-05       Impact factor: 2.014

5.  Human papillomaviruses and other influences on survival from cervical cancer in Panama.

Authors:  R C DeBritton; A Hildesheim; S L De Lao; L A Brinton; P Sathya; W C Reeves
Journal:  Obstet Gynecol       Date:  1993-01       Impact factor: 7.661

6.  The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells.

Authors:  T M Chen; C A Chen; C Y Hsieh; D Y Chang; Y H Chen; V Defendi
Journal:  Oncogene       Date:  1993-06       Impact factor: 9.867

7.  Human papillomavirus DNA sequences in adenocarcinoma of the uterine cervix in Indian women.

Authors:  B C Das; V Gopalkrishna; D K Das; J K Sharma; V Singh; U K Luthra
Journal:  Cancer       Date:  1993-07-01       Impact factor: 6.860

8.  Human papillomavirus (HPV) infection, HIV infection and cervical cancer in Tanzania, east Africa.

Authors:  J ter Meulen; H C Eberhardt; J Luande; H N Mgaya; J Chang-Claude; H Mtiro; M Mhina; P Kashaija; S Ockert; X Yu
Journal:  Int J Cancer       Date:  1992-06-19       Impact factor: 7.396

9.  Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity.

Authors:  H Romanczuk; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

10.  Human papillomavirus and invasive cervical cancer in Brazil.

Authors:  J Eluf-Neto; M Booth; N Muñoz; F X Bosch; C J Meijer; J M Walboomers
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

View more
  54 in total

1.  Integration of human papillomavirus 18 DNA in esophageal carcinoma 109 cells.

Authors:  Ke Zhang; Jin-Tao Li; Shu-Ying Li; Li-Hua Zhu; Ling Zhou; Yi Zeng
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  High prevalence of oncogenic HPV-16 in cervical smears of asymptomatic women of eastern Uttar Pradesh, India: a population-based study.

Authors:  Shikha Srivastava; Sadhana Gupta; Jagat Kumar Roy
Journal:  J Biosci       Date:  2012-03       Impact factor: 1.826

3.  Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types.

Authors:  Tarik Gheit; Stefano Landi; Federica Gemignani; Peter J F Snijders; Salvatore Vaccarella; Silvia Franceschi; Federico Canzian; Massimo Tommasino
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

4.  Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer.

Authors:  M Branca; C Giorgi; D Santini; L Di Bonito; M Ciotti; A Benedetto; P Paba; S Costa; D Bonifacio; P Di Bonito; L Accardi; C Favalli; K Syrjänen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

5.  Integration sites of human papillomavirus 18 in esophageal cancer samples.

Authors:  Shuying Li; Zhanjun Liu; Jianghong Yan; Shangbo Sun; Xiaoli Hou; Dianqing Liu; Ke Zhang; Jin-Tao Li
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

6.  Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens.

Authors:  Véronique Fontaine; Corinne Mascaux; Christine Weyn; Aurore Bernis; Nathalie Celio; Philippe Lefèvre; Leonard Kaufman; Christian Garbar
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

7.  Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions.

Authors:  F Bottari; M Sideri; C Gulmini; S Igidbashian; A Tricca; C Casadio; S Carinelli; S Boveri; D Ejegod; J Bonde; M T Sandri
Journal:  J Clin Microbiol       Date:  2015-04-22       Impact factor: 5.948

8.  Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV assay for human papillomavirus genotyping.

Authors:  C Estrade; R Sahli
Journal:  J Clin Microbiol       Date:  2013-12-11       Impact factor: 5.948

9.  Human papillomavirus type 16 status in cervical carcinoma cell DNA assayed by multiplex PCR.

Authors:  Krzysztof Lukaszuk; Joanna Liss; Izabela Wozniak; Janusz Emerich; Czesław Wójcikowski
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

10.  Down-regulated nucleoside diphosphate kinase nm23-H1 expression is unrelated to high-risk human papillomavirus but associated with progression of cervical intraepithelial neoplasia and unfavourable prognosis in cervical cancer.

Authors:  M Branca; C Giorgi; M Ciotti; D Santini; L Di Bonito; S Costa; A Benedetto; D Bonifacio; P Di Bonito; P Paba; L Accardi; L Mariani; M Ruutu; C Favalli; K Syrjänen
Journal:  J Clin Pathol       Date:  2006-03-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.